Moleculin Biotech Valuation
| MBRX Stock | USD 4.35 0.25 5.43% |
At this time, the firm appears to be overvalued. Moleculin Biotech secures a last-minute Real Value of $4.42 per share. The latest price of the firm is $4.35. Our model forecasts the value of Moleculin Biotech from analyzing the firm fundamentals such as Shares Owned By Insiders of 4.64 %, return on equity of -0.76, and Current Valuation of (12.73 M) as well as examining its technical indicators and probability of bankruptcy. In general, most investors recommend acquiring undervalued stocks and dropping overvalued stocks since, at some point, asset prices and their ongoing real values will merge together. Key fundamental drivers impacting Moleculin Biotech's valuation include:
Price Book 0.3953 | Enterprise Value -12.7 M | Enterprise Value Ebitda 0.4294 |
Overvalued
Today
Please note that Moleculin Biotech's price fluctuation is risky at this time. Calculation of the real value of Moleculin Biotech is based on 3 months time horizon. Increasing Moleculin Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Moleculin Biotech is useful when determining the fair value of the Moleculin stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Moleculin Biotech. Since Moleculin Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Moleculin Stock. However, Moleculin Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 4.35 | Real 4.42 | Target 8.0 | Hype 4.6 | Naive 4.61 |
The real value of Moleculin Stock, also known as its intrinsic value, is the underlying worth of Moleculin Biotech Company, which is reflected in its stock price. It is based on Moleculin Biotech's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Moleculin Biotech's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Moleculin Biotech's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Moleculin Biotech helps investors to forecast how Moleculin stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Moleculin Biotech more accurately as focusing exclusively on Moleculin Biotech's fundamentals will not take into account other important factors: Traditionally analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Moleculin Biotech's intrinsic value based on its ongoing forecasts of Moleculin Biotech's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Moleculin Biotech's closest peers. When choosing an evaluation method for Moleculin Biotech, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using both methods to arrive at a better estimate.
Moleculin Biotech Investments |
|
Moleculin Valuation Trend
Knowing Moleculin Biotech's actual value is paramount for traders to make sound investment determinations. Moleculin Biotech's real value is not only important for the investor to make better decisions but also for a more accurate overall view of Moleculin Biotech's financial worth over time since having this information enables investors and analysts to forecast the earnings more efficiently. Using both Moleculin Biotech's enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing descisions.
Moleculin Market Cap
Moleculin Biotech is rated below average in market capitalization category among related companies. Market capitalization of Health Care industry is now estimated at about 627.2 Million. Moleculin Biotech claims roughly 10.3 Million in market capitalization contributing just under 2% to equities under Health Care industry.Moleculin Biotech Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Moleculin Biotech's current stock value. Our valuation model uses many indicators to compare Moleculin Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Moleculin Biotech competition to find correlations between indicators driving Moleculin Biotech's intrinsic value. More Info.Moleculin Biotech is rated below average in price to earning category among related companies. It is rated below average in price to book category among related companies . Price To Book Ratio is likely to drop to 0.93 in 2024. Comparative valuation analysis is a catch-all model that can be used if you cannot value Moleculin Biotech by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Moleculin Biotech's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Moleculin Biotech's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Moleculin Biotech's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Moleculin Biotech and how it compares across the competition.
About Moleculin Biotech Valuation
The stock valuation mechanism determines the current worth of Moleculin Biotech on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Moleculin Biotech. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Moleculin Biotech based exclusively on its fundamental and basic technical indicators. By analyzing Moleculin Biotech's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Moleculin Biotech's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Moleculin Biotech. We calculate exposure to Moleculin Biotech's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Moleculin Biotech's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -127 K | -133.3 K | |
| Pretax Profit Margin | 0.00 | 0.00 | |
| Operating Profit Margin | 0.00 | 0.00 | |
| Net Profit Margin | 0.00 | 0.00 | |
| Gross Profit Margin | 0.00 | 0.00 |
8 Steps to conduct Moleculin Biotech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Moleculin Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Moleculin Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Moleculin Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Moleculin Biotech's revenue streams: Identify Moleculin Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Moleculin Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Moleculin Biotech's growth potential: Evaluate Moleculin Biotech's management, business model, and growth potential.
- Determine Moleculin Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Moleculin Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Moleculin Biotech Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Moleculin Biotech does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 2 M |
Moleculin Biotech Current Valuation Indicators
Valuation refers to the process of determining the present value of Moleculin Biotech and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Moleculin we look at many different elements of the entity such as Moleculin's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation. Moleculin Biotech's valuation analysis is also a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Moleculin Biotech's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Moleculin Biotech, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Moleculin Biotech's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Moleculin Biotech's worth.When determining whether Moleculin Biotech offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Moleculin Biotech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Moleculin Biotech Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Moleculin Biotech Stock: Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Complementary Tools for Moleculin Stock analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (15.15) | Return On Assets (0.39) | Return On Equity (0.76) |
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Moleculin Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.